Surfactant Replacement Therapy

Artificial Surfactant: Prophylaxis for Respiratory Distress Syndrome.- Rapid Response of Oxygenation, Slow Response of Compliance After Liposomal Phospholipid Substitution in Respiratory Distress Syndrome.- Impact of Surfactant Therapy on Bronchopulmonary Dysplasia.- Alveolar Atelectasis as a Mechanism for Infantile Apnoea: A Possible Role for Exogenous Surfactant Therapy?.- Changes in Pulmonary and Cerebral Blood Flow After Surfactant Treatment for Severe Respiratory Distress Syndrome.- IV: Surfactant Replacement in ARDS and Other Lung Diseases.- The Future for Surfactant Therapy of the Adult Respiratory Distress Syndrome.- Surfactant Replacement in Acute Respiratory Failure: Animal Studies and First Clinical Trials.- Pulmonary Surfactant Effects and Replacement in Oxygen Toxicity and Other ARDS-Type Lung Injuries.- Surfactant Replacement in Respiratory Failure Induced by Aspiration of Hydrochloric Acid in Rabbits.- Efficacy of Exogenous Surfactant in Experimental Aspiration Trauma.- Acute Effects of an Artificial Surfactant (Exosurf) Administered as an Aerosol in Sheep with Oleic Acid-Induced Lung Injury.- Discussion: What is the Surfactant of Choice for Replacement Therapy?.- V: What Happens After Surfactant Replacement Therapy?.- What Happens to Treatment Doses of Surfactant?.- Distribution of Exogenous Surfactant in Premature Lambs: High-Frequency Oscillation Ventilation Versus Conventional Mechanical Ventilation.- Immunohistochemical Study of the Distribution of Exogenous Surfactant in the Lungs of Surfactant-Deficient Rabbits Using a Monoclonal Antibody.- Immunogenicity of Surfactant and Its Implications for Replacement Therapy.- Surfactant Treatment of Newborn Rabbits Impedes Intrapulmonary Phagocytic Killing of Inhaled Group B Streptococci.- Effect of Bovine Surfactant on Mucus Secretion from Tracheal Submucosal Glands.- VI: Prospects for the Future.- The Bronchoalveolar Surfactant System Inhibits the Cardiovascular Effects of Angiotensin II, Serotonin, and Platelet-Activating Factor.- Artificial Surfactants Based on Different Hydrophobic Low-Molecular-Weight Proteins.- Reconstitution of Human Surfactant Activity Using Low-Molecular-Weight Apoproteins.- The Macromolecular Organization of Canine Lung Surfactant Protein SP 28-36: Structural Homology with the Complement Factor C1q.- Two-Step Substitution of Surfactant in Fetal Minipigs.- VII: Lipid Metabolism and Its Influence by Pharmacological Means.- Regulation of Phosphatidylcholine Synthesis in Type II Alveolar Epithelial Cells.- A Controlled Trial of CPD-Choline Administration in Premature Infants with Respiratory Distress Syndrome.- Effects of the ?2-Adrenoceptor-Stimulating Agent Terbutaline and Its Antagonist ICI 118.551 on Rat Lung Surfactant (Phospholipid) Metabolism.